TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis.

MLA

Gisondi, Paolo, et al. “TNF-α Inhibitors Biosimilars as First Line Systemic Treatment for Moderate-to-Severe Chronic Plaque Psoriasis.” Expert Review of Clinical Immunology, vol. 16, no. 6, June 2020, pp. 591–98. EBSCOhost, https://doi.org/10.1080/1744666X.2020.1771182.

APA

Gisondi, P., Geat, D., Conti, A., Dapavo, P., Piaserico, S., De Simone, C., Bianchi, L., Costanzo, A., Malagoli, P., Malara, G., Micali, G., Naldi, L., Offidani, A., Patrizi, A., Prignano, F., Parodi, A., Rongioletti, F., Calzavara-Pinton, P., & Girolomoni, G. (2020). TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. Expert Review of Clinical Immunology, 16(6), 591–598. https://doi.org/10.1080/1744666X.2020.1771182

Chicago

Gisondi, Paolo, Davide Geat, Andrea Conti, Paolo Dapavo, Stefano Piaserico, Clara De Simone, Luca Bianchi, et al. 2020. “TNF-α Inhibitors Biosimilars as First Line Systemic Treatment for Moderate-to-Severe Chronic Plaque Psoriasis.” Expert Review of Clinical Immunology 16 (6): 591–98. doi:10.1080/1744666X.2020.1771182.